Autotransfusion Devices Market Report 2026

Autotransfusion Devices Market Overview

• Autotransfusion Devices market size has reached to $1.26 billion in 2025 • Expected to grow to $1.8 billion in 2030 at a compound annual growth rate (CAGR) of 7.4% • Growth Driver: Autotransfusion Device Market Soars Amidst Rising Prevalence Of Cardiovascular Diseases • Market Trend: Innovative Solutions To Optimize Blood Recovery And Enhance Patient Outcomes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Autotransfusion Devices Market?

Autotransfusion devices refer to tools used to collect and reinfuse a patient's blood during a medical procedure, instead of using donated blood. This process is also known as autologous blood transfusion and can help reduce the need for allogenic (separate-donor) blood transfusions. Autotransfusion devices are commonly used in trauma patients in the emergency department and during surgeries. The main products included in the autotransfusion devices include autotransfusion systems, consumables and accessories. Autotransfusion systems refer to medical devices and techniques that allow a patient to receive their blood for a transfusion, instead of using blood from a separate donor. They are used for various applications including cardiovascular surgeries, orthopedic surgeries, neurological surgeries, obstetrics and gynecology surgeries, and other applications for use in various end-users such as hospitals, specialty clinics, and other end users.

What Is The Autotransfusion Devices Market Growth Forecast?

The autotransfusion devices market size is expected to see strong growth in the next few years. It will grow to $1.8 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing focus on cost-effective surgical care, rising adoption of minimally invasive surgeries, expansion of patient blood management programs, growing demand for automated autotransfusion devices, continuous innovation in disposable consumables. Major trends in the forecast period include increasing adoption of blood conservation technologies, rising use of autologous transfusion in surgeries, growing demand for advanced cell salvage systems, expansion of emergency autotransfusion applications, enhanced focus on patient blood management.

Global Autotransfusion Devices Market Segmentation

1) By Product Type: Autotransfusion Systems, Consumables And Accessories 2) By Application: Cardiovascular Surgeries, Orthopedic Surgeries, Neurological Surgeries, Other Applications 3) By End-Use: Hospitals, Trauma Centers & Emergency Departments, Other End Users Subsegments: 1) By Autotransfusion Systems: Surgical Autotransfusion Systems, Emergency Autotransfusion Systems, Continuous Flow Autotransfusion Systems 2) By Consumables And Accessories: Collection Reservoirs, Blood Filters, Tubing Sets, Pumps, Anticoagulants

What Are The Drivers Of The Autotransfusion Devices Market?

The increasing prevalence of cardiovascular diseases is expected to propel the growth of the autotransfusion device market going forward. Cardiovascular diseases (CVDs) refer to a group of disorders affecting the heart and blood vessels. Autotransfusion devices contribute to the trend of minimizing the use of allogeneic blood transfusions. Allogeneic transfusions involve donated blood from external sources, and autotransfusion allows for the reinfusion of the patient's blood, reducing the risk of transfusion reactions and complications associated with donor blood. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024 up 4.0% from 224.4 per 100,000 in 2023. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the autotransfusion device industry. The increasing demand for blood conservation is expected to drive the growth of the autotransfusion devices market. Blood conservation in surgical procedures refers to the practice of avoiding allogeneic blood transfusions during and after surgery to improve patient outcomes and protect their rights. Autotransfusion devices can be used in surgical procedures to reduce blood loss and improve patient outcomes. For instance, according to a report published in June 2023 by the World Health Organization (WHO), a Switzerland-based intergovernmental organization, 73% of reporting countries, or 125 out of 171, had a national blood policy. Overall, 66% of reporting countries, or 113 out of 171, have specific legislation covering the safety and quality of blood transfusion including 79% of high-income countries, 63% of middle-income countries, and 39% of low-income countries. Therefore, the increasing demand for blood conservation is driving the growth of the autotransfusion devices industry.

Key Players In The Global Autotransfusion Devices Market

Major companies operating in the autotransfusion devices market are Haemonetics Corporation, Medtronic plc, LivaNova plc, Terumo Corporation, Fresenius SE & Co. KGaA, B. Braun Melsungen AG, Asahi Kasei Medical Co. Ltd., Getinge AB, Baxter International Inc., Nipro Corporation, Teleflex Incorporated, Stryker Corporation, Braile Biomédica, Redax S.p.A., Gen World Medical Devices Corporation, Beijing ZKSK Technology Co. Ltd., Beijing Jingjing Medical Equipment Co. Ltd., Brightwake Ltd., Dideco, Atrium Medical Technologies

Global Autotransfusion Devices Market Trends and Insights

Major companies operating in the autotransfusion devices market are focused on developing technologically advanced solutions, such as next-generation intelligent control software to enhance precision, efficiency, and patient outcomes during blood transfusions. Next-generation intelligent control software in autotransfusion devices refers to advanced algorithms that optimize blood recovery, processing, and reinfusion in real-time, enhancing efficiency and patient safety. For instance, in March 2023, Haemonetics Corporation, a US-based provider of blood and plasma supplies and services, announced the U.S. Food and Drug Administration (FDA) clearance of Cell Saver Elite+ Autotransfusion System, the next-generation software, which maximizes the recovery of red blood cells during surgical procedures with potential medium to high blood loss. This innovative upgrade simplifies autotransfusion operations, reduces unnecessary allogeneic transfusions and ultimately improves patient outcomes.

Regional Outlook

North America was the largest region in the autotransfusion devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global autotransfusion devices market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Autotransfusion Devices Market?

The autotransfusion devices market consists of sales of on-pump transfusion devices and off-pump transfusion devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.